PEAT Act of 2026 Protecting Equal Access to Thyroid Act of 2026
To amend the Public Health Service Act to prohibit treatment of a biologic as a biological product based solely on the presence of a protein that is a clinically inactive component in such biologic, and for other purposes.
This bill, known as the PEAT Act of 2026, aims to amend the Public Health Service Act. It seeks to ensure that a biologic product cannot be treated as a biological product simply because it contains a protein that is not active in clinical use. This means that if a protein in a biologic is not essential for its therapeutic effect, it should not be a reason to classify the entire biologic differently. This could impact patients and healthcare providers by ensuring consistent treatment standards and potentially expanding access to certain biologics.
The bill would primarily affect those involved in the development, regulation, and use of biologic products, including pharmaceutical companies, healthcare providers, and patients. By clarifying the criteria for classifying biologics, it could lead to more effective and accessible treatments for various conditions.
As of the last update, HB8630 was introduced and referred to the House Committee on Energy and Commerce on April 30, 2026. This means it is in the early stages of the legislative process, where it will be reviewed and potentially marked up by the committee before moving forward.
